Develop products based on C-peptide for treatment of long-term complications in patients with Type 1 diabetes
Initial Focus: Type 1 diabetes neuropathy (3 million patients, no treatment available)
Extend therapies to prevent Type 1 diabetes long-term complications (est. 15 million patients)

Anticipated treatment regimen: life long, daily dose